Latest Regulatory Filings News

Neurizon’s first participant in the 250-person Regimen I ALS trial has completed the 36-week randomised phase and entered an optional active treatment extension. The milestone keeps the program on track for topline results in late Q2 2027, while recent FDA feedback points to a potential single-trial approval pathway if the data meet regulatory standards.

Imricor Medical Systems (ASX:IMR) has moved from regulatory preparation into US commercial deployment, signing its first two NorthStar hospital customers within weeks of launch. The milestone comes with sharply higher quarterly revenue, a fresh Philips pathway and a still-heavy cash burn.

Tamboran Resources has recorded the first gas sales from the Beetaloo Basin, delivering 0.31 Bcf and US$1.8 million during the September quarter. Stronger Shenandoah South well results mark genuine operational progress, but commissioning-stage accounting, continuing losses and future funding needs keep the milestone provisional.

WCM Global Growth has raised its fully franked quarterly dividend to 2.45 cents per share and signalled further increases through September 2027. The planned payments imply 10.1 cents per share over the next 12 months, although future distributions remain conditional on reserves and franking credits.

Bridge SaaS ended September with just A$31,000 in cash after a A$1.455 million operating outflow, leaving an estimated 0.02 quarters of funding. The company says its solvency depends on lower costs and timely NDIS receipts, while a potential A$2 million placement remains uncommitted.

Audalia Resources has lodged the key development and closure proposal for its Medcalf titanium-vanadium-iron project in Western Australia. The milestone advances the permitting process, but construction, financing and production remain dependent on further approvals and a final investment decision.

Atomic Eagle has received approximately A$10.9 million after its largest shareholder exercised 35.1 million options ahead of their May 2027 expiry. The funding strengthens the uranium developer’s balance sheet, while the new shares expand the company’s capital base.

Uscom Limited (ASX:UCM) reported no customer receipts and just A$2,000 in cash at 30 September, as the former medical-device business moves into a minimal-activity phase. The company is now seeking an acquisition and a possible strategic relisting.

EBR Systems delivered higher reimbursement, manufacturing and revenue milestones in the third quarter, but a sharp September slowdown and a formal going-concern warning have shifted attention to execution and funding. The company says it holds US$93.2 million in cash, cash equivalents and marketable securities, while US$41.8 million of debt falls due within 12 months.

Moderna returned to quarterly GAAP profit, raised its 2026 revenue growth outlook and reported positive Phase 3 melanoma data. The stronger quarter was supported by international COVID vaccine sales, while cash generation and pipeline execution remain important tests.

BTC Health has expanded its exclusive ExoVasc PEARS distribution rights from Australia into India under a new five-year agreement. The opportunity is potentially significant, but Indian sales remain dependent on CDSCO import approval.

Regency Centers lifted its 2026 outlook and increased its quarterly common dividend by 6% after stronger third-quarter operating results. The upbeat performance came alongside a sharp decline in GAAP net income, driven partly by a US$65.1 million real estate impairment charge.